

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Michael E. Jung *et al.*

Art Unit: 1614

Application No: 10/590,445

Examiner: Savitha M. Rao

Confirmation No: 6734

Filed: August 24, 2006

Atty. Docket No: 58086-235854

For: METHODS AND MATERIALS FOR
ASSESSING PROSTATE CANCER
THERAPIES AND COMPOUNDS

Customer No:

26694

PATENT TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir/Madam:

Pursuant to 37 C.F.R. §§1.56, 1.97, and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references A54-55, B42, and C138b and C141 listed on the attached PTO/SB/08. Applicant notes that the reference C138b was previously submitted as reference C138, but that the present citation for C138b is corrected from that for C138. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 C.F.R. §1.97(b)(3)). Therefore, the undersigned understands that no fee is due for the filing of this Information Disclosure Statement.

In accordance with 37 C.F.R. §1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).


In accordance with 37 C.F.R. §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(a) exists. In accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication, or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 C.F.R. §1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0261, under Order No. 58086-235854.

Dated: December 9, 2009

Respectfully submitted,

By 

Lars H. Genieser, Ph.D.

Registration No.: 46,722

VENABLE LLP

P.O. Box 34385

Washington, DC 20043-9998

(202) 344-4000

(202) 344-8300 (Fax)

Attorney/Agent For Applicant

DC2/1078370